Stokes Family Office LLC Acquires 110 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Stokes Family Office LLC boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 12.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 965 shares of the medical equipment provider’s stock after purchasing an additional 110 shares during the period. Stokes Family Office LLC’s holdings in Intuitive Surgical were worth $385,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC raised its stake in shares of Intuitive Surgical by 7.0% in the third quarter. Integrated Wealth Concepts LLC now owns 4,138 shares of the medical equipment provider’s stock valued at $1,209,000 after acquiring an additional 271 shares during the last quarter. Harbour Investments Inc. raised its stake in shares of Intuitive Surgical by 13.7% in the third quarter. Harbour Investments Inc. now owns 1,056 shares of the medical equipment provider’s stock valued at $309,000 after acquiring an additional 127 shares during the last quarter. Creative Planning raised its stake in shares of Intuitive Surgical by 7.8% in the third quarter. Creative Planning now owns 51,844 shares of the medical equipment provider’s stock valued at $15,153,000 after acquiring an additional 3,754 shares during the last quarter. Comerica Bank raised its stake in shares of Intuitive Surgical by 427.8% in the third quarter. Comerica Bank now owns 106,655 shares of the medical equipment provider’s stock valued at $31,174,000 after acquiring an additional 86,449 shares during the last quarter. Finally, USA Financial Formulas acquired a new stake in shares of Intuitive Surgical in the third quarter valued at approximately $205,000. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 0.1 %

Shares of ISRG stock traded up $0.66 on Friday, reaching $444.16. The stock had a trading volume of 1,151,588 shares, compared to its average volume of 1,505,798. The firm’s 50-day moving average is $417.08 and its two-hundred day moving average is $390.41. The firm has a market capitalization of $157.54 billion, a price-to-earnings ratio of 80.17, a P/E/G ratio of 5.74 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $449.00.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the business posted $1.00 EPS. The business’s revenue was up 11.5% compared to the same quarter last year. On average, sell-side analysts forecast that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ISRG. Evercore ISI raised their price target on shares of Intuitive Surgical from $385.00 to $425.00 and gave the company an “in-line” rating in a report on Tuesday, July 2nd. The Goldman Sachs Group assumed coverage on shares of Intuitive Surgical in a report on Thursday, May 30th. They set a “buy” rating and a $500.00 target price for the company. Robert W. Baird lowered their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a report on Friday, April 19th. Citigroup lifted their target price on shares of Intuitive Surgical from $462.00 to $512.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Jefferies Financial Group lifted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $410.32.

Insider Transactions at Intuitive Surgical

In other news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares of the company’s stock, valued at $9,385,753.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Myriam Curet sold 5,318 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at approximately $110,456.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,956 shares of company stock valued at $6,927,011. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.